The WHO Committee noted that stevioside has shown some evidence of pharmacological effects in patients with hypertension or with type-2 diabetes at doses corresponding to about 12.5–25mg/kgbw per day (equivalent to 5–10mg/kgbw per day expressed as steviol). The evidence available at present was inadequate to assess whether these pharmacological effects would also occur at lower levels of dietary exposure, which could lead to adverse effects in some individuals (e.g. those with hypotension or diabetes). The Committee therefore decided to allocate a temporary ADI, pending submission of further data on the pharmacological effects of steviol glycosides in humans.

World Health Organization Findings on Stevia: Evidence Shows Stevia Affects Patients With Hypertension and Type 2 Diabetes:

Pepsi to sell drinks with no-calorie sweetener derived from stevia shrub

Cargill rolling out natural, no-calorie sweetener

STEVIA REFERENCES AND RESEARCH STUDY

ARTICLES:

CBC Radio

Stevia by Science Tech, Entrepreneur

Copyright © 2008 | Site owned and operated by: EverStevia.com, All Rights Reserved.

Hosting by IPOWER™ | Bookmark this site! | contact us |

Disclaimer: The information provided on EverStevia.com is for educational purposes only and IS NOT intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek professional medical advice from your physician or other qualified healthcare provider with any questions you may have regarding a medical condition.